SN
SN.LSE Smith & Nephew PLC
- Market cap
- GBX 9.31B
- P/E
- 20.2x
- P/B
- 2.39x
- ROE
- 23.1%
- Dividend yield
- 2.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is SN.LSE undervalued?
Graham numberSN.LSE trades 46.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Smith & Nephew PLC fundamental analysis
No fundamental analysis for Smith & Nephew PLC yet.
Smith & Nephew PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used i…
Full company profileSmith & Nephew PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Smith & Nephew PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.67B | 4.77B | 4.90B | 5.14B | 4.56B | 5.21B | 5.22B | 5.55B | 5.81B | 6.16B | 12.3B |
| Gross Profit | 3.40B | 3.52B | 3.61B | 3.80B | 3.16B | 3.67B | 3.68B | 3.82B | 4.05B | 4.28B | 8.71B |
| Operating Income | 801M | 934M | 863M | 815M | 295M | 593M | 315M | 425M | 657M | 1.02B | 1.90B |
| EBITDA | 1.27B | 1.39B | 1.29B | 1.34B | 866M | 1.24B | 874M | 956M | 1.24B | 1.60B | 3.09B |
| Net Income | 784M | 767M | 663M | 600M | 448M | 524M | 223M | 263M | 412M | 625M | 1.20B |
| EPS | 0.88 | 0.88 | 0.76 | 0.69 | 0.51 | 0.60 | 0.25 | 0.30 | 0.47 | 0.72 | 1.40 |
| Balance Sheet | |||||||||||
| Total Assets | 7.34B | 7.87B | 8.06B | 9.30B | 11.0B | 10.9B | 9.97B | 9.99B | 10.4B | 10.5B | 11.1B |
| Total Liabilities | 3.39B | 3.22B | 3.19B | 4.16B | 5.73B | 5.35B | 4.71B | 4.77B | 5.09B | 5.17B | 5.86B |
| Shareholders' Equity | 3.96B | 4.64B | 4.87B | 5.14B | 5.28B | 5.57B | 5.26B | 5.22B | 5.27B | 5.29B | 5.21B |
| Cash & Short-term Investments | 100M | 169M | 365M | 277M | 1.76B | 1.29B | 350M | 302M | 619M | 557M | 758M |
| Total Debt | 1.65B | 1.45B | 1.47B | 2.05B | 3.69B | 3.34B | 2.87B | 3.08B | 3.32B | 3.33B | 3.80B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 849M | 1.09B | 931M | 1.17B | 935M | 877M | 468M | 608M | 987M | 1.31B | 1.79B |
| Capital Expenditure | 392M | 376M | 347M | 408M | 443M | 408M | 358M | 427M | 381M | 442M | 754M |
| Free Cash Flow | 457M | 714M | 584M | 760M | 492M | 469M | 110M | 181M | 606M | 870M | 1.03B |
| Ratios | |||||||||||
| ROE | 19.8% | 16.5% | 13.6% | 11.7% | 8.5% | 9.4% | 4.2% | 5.0% | 7.8% | 11.8% | 23.1% |
| ROA | 10.7% | 9.8% | 8.2% | 6.5% | 4.1% | 4.8% | 2.2% | 2.6% | 4.0% | 6.0% | 10.9% |
| Net Profit Margin | 16.8% | 16.1% | 13.5% | 11.7% | 9.8% | 10.1% | 4.3% | 4.7% | 7.1% | 10.1% | 9.8% |
| Debt to Equity | 0.42x | 0.31x | 0.30x | 0.40x | 0.70x | 0.60x | 0.55x | 0.59x | 0.63x | 0.63x | 0.73x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Smith & Nephew PLC dividends
- Dividend yield
- 2.66%
- Forward dividend
- 0.29 GBX
- Payout ratio
- 53.9%
- Ex-dividend date
- Oct 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 337M | 0.39 | 53.9% |
| 2024 | USD 327M | 0.37 | 79.4% |
| 2023 | USD 327M | 0.37 | 124.3% |
| 2022 | USD 327M | 0.37 | 146.6% |
| 2021 | USD 329M | 0.37 | 62.8% |
| 2020 | USD 328M | 0.37 | 73.2% |
| 2019 | USD 318M | 0.36 | 53.0% |
| 2018 | USD 321M | 0.37 | 48.4% |
| 2017 | USD 269M | 0.31 | 35.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 9:11 on Aug 7, 2000.
Who owns Smith & Nephew PLC
- Insiders 0.24%
- Institutions 74.14%
- Public & others 25.62%
- Shares outstanding 837M
- Free float 843M
Smith & Nephew PLC company profile
- Company name
- Smith & Nephew PLC
- Ticker
- SN.LSE
- ISIN
- GB0009223206
- Exchange
- London Exchange
- Listed since
- Nov 16, 1999
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 17,000
- Fiscal year end
- December
- Address
- Building 5, Watford, United Kingdom, WD18 8YE
- Phone
- 44 1923 477 100
- Website
- smith-nephew.com
About Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Smith & Nephew PLC management
10- Dr. Deepak S. Nath Ph.D.CEO & Director · born 1972
- Mr. Pierre PalassianInterim CFO, Senior VP of Finance & Group Controller
- Mr. Paul ConnollyPresident of Global Operations · born 1968
- Emily HeavenHead of Investor Relations
- Ms. Helen BarracloughGroup General Counsel & Company Secretary · born 1979
- Ms. Alison ParkesChief Compliance Officer & Compliance APAC · born 1972
- Mr. Charles ReynoldsHead of Corporate Communication
- Dr. Ajay Dhankhar Ph.D.Chief Corporate Development & Strategy Officer · born 1971
- Ms. Elga LohlerChief Human Resources Officer · born 1968
- Dr. Vasant Padmanabhan Ph.D.President Research & Development, ENT and Emerging Markets · born 1967